Antiviral Drugs - NAFTA

NAFTA

In 2024, the projected revenue for the Antiviral Drugs market is estimated to reach US$31.73bn.
This market is expected to experience a steady annual growth rate (CAGR 2024-2029) of 1.37%, leading to a market volume of US$33.96bn by 2029.
When comparing globally, United States is anticipated to generate the highest revenue, with US$30,640.00m in 2024.
It is important to note that the Antiviral Drugs market is a significant market within the pharmaceutical industry, and these numbers reflect its potential growth and market dominance.
Additionally, it is worth mentioning that these figures pertain to the NAFTA region, encompassing United States, Canada, and Mexico.
The demand for antiviral drugs in NAFTA countries has surged due to the increasing prevalence of viral diseases.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

Antiviral drugs have become increasingly important in the healthcare industry due to the rise of viral infections. The North American Free Trade Agreement (NAFTA) region has seen a significant development in the Antiviral Drugs market.

Customer preferences: Customers in NAFTA are becoming more aware of the benefits of antiviral drugs in treating viral infections. The demand for these drugs has increased due to the prevalence of viral infections such as HIV, hepatitis, and influenza. Customers in the region are also becoming more concerned about the side effects of these drugs and are looking for alternatives that have fewer side effects.

Trends in the market: The Antiviral Drugs market in the United States is the largest in NAFTA due to the high prevalence of viral infections. The market is dominated by a few key players, and there is intense competition among them. The market is expected to grow due to an increase in the number of people suffering from viral infections and the development of new drugs.In Canada, the Antiviral Drugs market is also growing due to an increase in the number of people suffering from viral infections. The market is dominated by a few key players, and there is intense competition among them. The Canadian government is also taking steps to reduce the cost of these drugs, which is expected to increase demand.In Mexico, the Antiviral Drugs market is still in its early stages of development. However, the market is expected to grow due to an increase in the number of people suffering from viral infections and the development of new drugs. The Mexican government is also taking steps to improve access to these drugs, which is expected to increase demand.

Local special circumstances: The United States has a large population of people with viral infections, which has led to a high demand for Antiviral Drugs. The market is also highly regulated, which has led to intense competition among key players. The Canadian government is taking steps to reduce the cost of these drugs, which is expected to increase demand. The Mexican government is also taking steps to improve access to these drugs, which is expected to increase demand.

Underlying macroeconomic factors: The Antiviral Drugs market in NAFTA is expected to grow due to an increase in the number of people suffering from viral infections. The market is also expected to benefit from the development of new drugs. The healthcare industry in NAFTA is highly regulated, which has led to intense competition among key players. The cost of these drugs is also a concern for customers, which has led to the development of alternatives with fewer side effects.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.